Alzheon bolsters executive staff in preparation for launch of new Alzheimer’s drug
Image | Courtesy of Google Maps
Alzheon headquarters in Framingham. The company is working on a drug to treat Alzheimer's.
Alzheon, a Framingham-based biopharmaceutical company, has promoted Glenn Pauly to chief commercial officer and appointed two new vice presidents in preparation for the commercial launch of a new investigational agent that aims to slow and potentially prevent early Alzheimer’s disease.
Pauly joined Alzheon in July 2022, where he helped the company begin preparation for the launch of ALZ-801, which has the potential to become the first oral agent that can slow and prevent early Alzheimer’s, according to a release made by the company on Tuesday.
“Alzheon’s novel therapeutic approach has an opportunity to transform the standard of care and improve access to treatment for all Alzheimer’s patients.” Dr. Martin Tolar, founder, president and CEO of Alzheon, said in the release.
Pauly has more than 20 years of commercial launch experience, previously serving as the division general manager and vice president at Cambridge-based Biogen, according to Alzehon’s website. He received his bachelor’s degree in communications from Loras College in Iowa.
Pauly replaced Peter Laivins as the company’s chief commercial officer. Laivins is now a board member of Genexine, a pharmaceutical company based in South Korea.
In addition the promotion of Pauly, Alzehon announced the appointment of Dina Lynch to vice president of market access, and Nate Greene to vice president of brand marketing.
Lynch joined Alzehon from Ireland-based Nabriva Therapeutics, where shes served as vice president of sales and managed care. Greene previously served in commercial and executive roles at several pharmaceutical companies, including Biogen. Alzheon didn’t specify who Lynch and Green replaced.
“We are committed to delivering a disruptive option to the Alzheimer’s disease market as quickly as possible and I am excited to have Dina and Nate join the commercial team,” Pauly said in the statement. “Their depth of experience and understanding of access pathways and marketing strategies are what we need during this crucial period. Having these strong leaders further enhances our ability to establish critical partnerships and patient advocacy programs to support a successful commercial launch in 2025.”
WBJ Web Partners
Most Recent
Most Recent
0 Comments